Paper 66 - LONG TERM FOLLOW-UP OF MTOR INHIBITORS AND EXEMESTANE TREATMENT IN PRECOMA PATIENTS PROGRESSING TO MTOR INHIBITORS ALONE. RESULTS FROM TWO EUROPEAN REFERRAL CENTERS

Author(s)

• 

  Chiara Fabbroni

  Dr
  Fondazione IRCCS Istituto Nazionale dei Tumori MILANO
  milano, Lombardia, Italy

  Slides PDF

Co-Author(s)

• PH

  Paul Huang, n/a

  The Institute for Cancer Research
  London, England, United Kingdom
• AL

  Axel Le Cesne, MD

  Department of Medicine, Gustave Roussy
  Villejuif, Ile-de-France, France
• EF

  Elena R. Fumagalli, MD

  Istituto Nazionale Tumori
  Milano, Lombardia, Italy
• SP

  Salvatore Provenzano, n/a

  Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
  milano, Lombardia, Italy
• 

  Andrea Franza, MD (he/him/his)

  Medical Oncology Resident
  Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
  Milan, Lombardia, Italy
• CM

  Carlo Morosi, MD

  Radiologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milano, Lombardia, Italy
• AD

  Angelo Dei Tos, MD, PhD

  Azienda Ospedaliera di Padova
  Padova, Veneto, Italy
• 

  Marta Barisella, MD (she/her/hers)

  Pathologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy
• 

  Robin Lewis L. Jones, MD

  MEDICAL ONCOLOGIST
  Royal Marsden Hospital and Institute of Cancer Research
  London, England, United Kingdom
• BV

  Benjamin Verret, n/a

  Institute Gustave Roussy- paris
  paris, Ile-de-France, France
• 

  Paolo G. Casali, MD

  Associate Professor in Medical Oncology
  University of Milan
  Milano, Lombardia, Italy
• 

  Roberta Sanfilippo, MD

  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milano, Lombardia, Italy